Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar
<h3>Background</h3><p dir="ltr">It is estimated that physicians prescribe antibiotics inappropriately in 50% of cases.1,2 We aimed to compare the economic advantage of mature antimicrobial stewardship program (ASP) versus premature ASP use in hematology and oncology setti...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513514078470144 |
|---|---|
| author | Dina Abushanab (10696501) |
| author2 | Diala Alhaj Moustafa (18472430) Bhagyasree Adampally Sankar (18472431) Ziad Nasr (18472432) Moza Al Hail (2511859) Anas Hamad (9545771) Palli Valappila Abdul Rouf (18472377) Wessam Elkassem (18472434) Binny Thomas (5801969) Daoud Al-Badriyeh (832403) |
| author2_role | author author author author author author author author author |
| author_facet | Dina Abushanab (10696501) Diala Alhaj Moustafa (18472430) Bhagyasree Adampally Sankar (18472431) Ziad Nasr (18472432) Moza Al Hail (2511859) Anas Hamad (9545771) Palli Valappila Abdul Rouf (18472377) Wessam Elkassem (18472434) Binny Thomas (5801969) Daoud Al-Badriyeh (832403) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dina Abushanab (10696501) Diala Alhaj Moustafa (18472430) Bhagyasree Adampally Sankar (18472431) Ziad Nasr (18472432) Moza Al Hail (2511859) Anas Hamad (9545771) Palli Valappila Abdul Rouf (18472377) Wessam Elkassem (18472434) Binny Thomas (5801969) Daoud Al-Badriyeh (832403) |
| dc.date.none.fl_str_mv | 2024-05-26T10:53:07Z |
| dc.identifier.none.fl_str_mv | 10.57945/manara.25709295.v1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/conference_contribution/Cost-benefit_analysis_of_antimicrobial_stewardship_program_in_a_cancer_setting_in_Qatar/25709295 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Economics Applied economics Microbial Stewardship Cost-benefit ratio Cancer Qatar Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| dc.title.none.fl_str_mv | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar |
| dc.type.none.fl_str_mv | Text Conference contribution info:eu-repo/semantics/publishedVersion text conference object |
| description | <h3>Background</h3><p dir="ltr">It is estimated that physicians prescribe antibiotics inappropriately in 50% of cases.1,2 We aimed to compare the economic advantage of mature antimicrobial stewardship program (ASP) versus premature ASP use in hematology and oncology settings in Qatar. </p><h3>Methods</h3><p dir="ltr">We investigated the economic benefits of a premature versus a mature ASP from the perspective of a hospital. Premature ASP was defined as the 12 months following the establishment of the ASP (May 2015-April 2016), while mature ASP was the most recent 12 months of ASP implementation at the National Center for Cancer Care and Research (NCCCR) (February 2019-January 2020). Patient records were retrospectively reviewed. The total economic benefit of the ASP maturity was calculated as the sum of the cost savings and the cost avoidance associated with the service minus the operational cost.3 Cost savings were the reduction in therapy cost linked to decreased antimicrobial consumption and resource utilization. Cost avoidance was the expenses saved due to decreased hospital stays and fewer adverse drug events (ADEs). Calculating the cost of an ADE involved assuming an additional 1- 2 days of hospital stay due to the ADE, based on a prior study (unpublished). The operational cost encompassed the time spent in ASP service. </p><h3>Results</h3><p dir="ltr">The benefit-to-cost ratio was 640, representing a benefit of 1,017 QAR generated for each 1 QAR invested in the ASP service. ASP maturity led to a substantial reduction in antimicrobial consumption and resource utilization by 1,248,666 QAR Mature ASP had lower avoidance cost, yielding a cost saving of QAR11,969,651. ASP maturity yielded a net benefit of 13,230,794 QAR. Mature ASP had lower operational costs, resulting in cost saving of 12,477 QAR (Figures 1-2).</p><h3>Conclusions</h3><p dir="ltr">The observed reductions in antimicrobials costs from reduced antimicrobial use and the added value of cost avoidance signify the positive impact of a well-established ASP.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_52453f939964658f4024a34e0d02c4b6 |
| identifier_str_mv | 10.57945/manara.25709295.v1 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25709295 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in QatarDina Abushanab (10696501)Diala Alhaj Moustafa (18472430)Bhagyasree Adampally Sankar (18472431)Ziad Nasr (18472432)Moza Al Hail (2511859)Anas Hamad (9545771)Palli Valappila Abdul Rouf (18472377)Wessam Elkassem (18472434)Binny Thomas (5801969)Daoud Al-Badriyeh (832403)Biomedical and clinical sciencesClinical sciencesOncology and carcinogenesisEconomicsApplied economicsMicrobialStewardshipCost-benefit ratioCancerQatarQatar Health Congress 2023 and the 3rd Qatar Public Health Conference<h3>Background</h3><p dir="ltr">It is estimated that physicians prescribe antibiotics inappropriately in 50% of cases.1,2 We aimed to compare the economic advantage of mature antimicrobial stewardship program (ASP) versus premature ASP use in hematology and oncology settings in Qatar. </p><h3>Methods</h3><p dir="ltr">We investigated the economic benefits of a premature versus a mature ASP from the perspective of a hospital. Premature ASP was defined as the 12 months following the establishment of the ASP (May 2015-April 2016), while mature ASP was the most recent 12 months of ASP implementation at the National Center for Cancer Care and Research (NCCCR) (February 2019-January 2020). Patient records were retrospectively reviewed. The total economic benefit of the ASP maturity was calculated as the sum of the cost savings and the cost avoidance associated with the service minus the operational cost.3 Cost savings were the reduction in therapy cost linked to decreased antimicrobial consumption and resource utilization. Cost avoidance was the expenses saved due to decreased hospital stays and fewer adverse drug events (ADEs). Calculating the cost of an ADE involved assuming an additional 1- 2 days of hospital stay due to the ADE, based on a prior study (unpublished). The operational cost encompassed the time spent in ASP service. </p><h3>Results</h3><p dir="ltr">The benefit-to-cost ratio was 640, representing a benefit of 1,017 QAR generated for each 1 QAR invested in the ASP service. ASP maturity led to a substantial reduction in antimicrobial consumption and resource utilization by 1,248,666 QAR Mature ASP had lower avoidance cost, yielding a cost saving of QAR11,969,651. ASP maturity yielded a net benefit of 13,230,794 QAR. Mature ASP had lower operational costs, resulting in cost saving of 12,477 QAR (Figures 1-2).</p><h3>Conclusions</h3><p dir="ltr">The observed reductions in antimicrobials costs from reduced antimicrobial use and the added value of cost avoidance signify the positive impact of a well-established ASP.</p>2024-05-26T10:53:07ZTextConference contributioninfo:eu-repo/semantics/publishedVersiontextconference object10.57945/manara.25709295.v1https://figshare.com/articles/conference_contribution/Cost-benefit_analysis_of_antimicrobial_stewardship_program_in_a_cancer_setting_in_Qatar/25709295CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257092952024-05-26T10:53:07Z |
| spellingShingle | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar Dina Abushanab (10696501) Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Economics Applied economics Microbial Stewardship Cost-benefit ratio Cancer Qatar Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| status_str | publishedVersion |
| title | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar |
| title_full | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar |
| title_fullStr | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar |
| title_full_unstemmed | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar |
| title_short | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar |
| title_sort | Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar |
| topic | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Economics Applied economics Microbial Stewardship Cost-benefit ratio Cancer Qatar Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |